| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/02/2004 | EP1424394A2 TAT transdominant variants from HIV virus |
| 06/02/2004 | EP1424393A2 Mammalian cytokine-like polypeptide-10 |
| 06/02/2004 | EP1424344A1 Modified cDNA factor VIII and its derivates |
| 06/02/2004 | EP1424082A1 Method of regenerating bone/chondral tissues by transferring transcriptional factor gene |
| 06/02/2004 | EP1423537A2 Compositions and methods for the prevention and treatment of huntington's disease |
| 06/02/2004 | EP1423428A2 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 06/02/2004 | EP1423424A2 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 06/02/2004 | EP1423422A2 A caspase- 8 binding protein, its preparation and use |
| 06/02/2004 | EP1423413A1 Peptidic compounds selectively binding to p-selectin |
| 06/02/2004 | EP1423406A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 06/02/2004 | EP1423404A2 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/02/2004 | EP1423138A2 Use of il-18 inhibitors in hypersensitivity disorders |
| 06/02/2004 | EP1423135A2 Methods for inhibiting angiogenesis |
| 06/02/2004 | EP1423128A2 Methods for the treatment of chronic pain anc compositions therefor |
| 06/02/2004 | CN1501976A Crf2 ligands in combination therapy |
| 06/01/2004 | US6743967 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| 06/01/2004 | US6743909 Being 20 to 80 nucleobases in length targeted to 1771 through 1790 of coding region; having at least one modified inter-nucleoside linkage, sugar moiety or nucleobase |
| 06/01/2004 | US6743781 Glycerolipid compounds useful for the transfer of an active substance into a target cell |
| 06/01/2004 | US6743779 Methods for delivering compounds into a cell |
| 06/01/2004 | US6743774 Tribonectins |
| 06/01/2004 | US6743631 Non-primate mammalian cell lines having no endogenous retroviral sequences for packaging; envelope proteins; gag/pol genes |
| 06/01/2004 | US6743628 Comprises neuron differentiation growth factor cultures; for treating neurodegenerative disorders |
| 06/01/2004 | US6743626 Artificial salivary gland |
| 06/01/2004 | US6743623 Viral recombinant vectors for expression in muscle cells |
| 06/01/2004 | US6743620 Comprises transgenic gag/pol gene expression systems; recombinases; antibiotic resistance; envelope proteins; vesicular stomatitis virus g-protein |
| 06/01/2004 | US6743577 Methods of using cyanovirins to inhibit viral infection |
| 06/01/2004 | US6743444 Method of making microencapsulated DNA for vaccination and gene therapy |
| 06/01/2004 | CA2170605C Mutants of the rb and p53 genes and uses thereof |
| 05/29/2004 | CA2451584A1 Modified cdna factor viii and its derivatives |
| 05/27/2004 | WO2004044245A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation |
| 05/27/2004 | WO2004044229A2 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A2 (PDE7a2) |
| 05/27/2004 | WO2004044199A1 Screening method |
| 05/27/2004 | WO2004044164A2 Method for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | WO2004044163A2 Methods for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | WO2004044141A2 Conjugated oligomeric compounds and their use in gene modulation |
| 05/27/2004 | WO2004044140A2 2’-substituted oligomeric compounds and compositions for use in gene modulations |
| 05/27/2004 | WO2004044137A2 Modified oligomeric compounds and compositions for use in gene modulation |
| 05/27/2004 | WO2004044135A2 Structural motifs and oligomeric compounds and their use in gene modulation |
| 05/27/2004 | WO2004044134A2 Phosphorous-linked oligomeric compounds and their use in gene modulation |
| 05/27/2004 | WO2004044131A2 Cross-linked oligomeric compounds and their use in gene modulation |
| 05/27/2004 | WO2004044008A1 Dna/rna transduction technology and its clinical and basic applications |
| 05/27/2004 | WO2004043990A2 Human stem cell materials and methods |
| 05/27/2004 | WO2004043978A2 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
| 05/27/2004 | WO2004043977A2 2’-fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| 05/27/2004 | WO2004043495A1 Delivery agent, method of delivering a target substance to cells, method for producing delivery agent, composition for producing delivery agent, and kit for producing delivery agent |
| 05/27/2004 | WO2004043494A1 Nitric oxide synthase gene transfer to the atrium for vagal tone increase |
| 05/27/2004 | WO2004043406A2 ENGINEERED RNAi ADENOVIRUS SILENCING EXPRESSION (ERASE) OF DNA REPAIR PROTEINS |
| 05/27/2004 | WO2004043399A2 Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| 05/27/2004 | WO2004043398A2 Modulation of jumonji expression |
| 05/27/2004 | WO2004043387A2 Compositions and methods for cancer diagnosis and therapy |
| 05/27/2004 | WO2004043386A2 Molecules preferentially associated with effector t cells and methods of their use |
| 05/27/2004 | WO2004043370A2 Methods and compositions for modulating activator protein 1 |
| 05/27/2004 | WO2004043353A2 Compositions and methods for treating acute myeloid leukemia |
| 05/27/2004 | WO2004043340A2 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 05/27/2004 | WO2004043232A2 Methods for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | WO2004043222A2 Treating carcinoid neoplasms with therapeuthic viruses |
| 05/27/2004 | WO2004035616A3 Adenovirus expressing genes in reverse order and use thereof |
| 05/27/2004 | WO2004034780A3 Method of producing recombinant proteins in the mammary gland of non-transgenic mammals |
| 05/27/2004 | WO2004033696A3 Recombinant adenoviral vectors and applications thereof |
| 05/27/2004 | WO2004012775A3 Bicistronic vector encoding a vegf and an fgf, use thereof |
| 05/27/2004 | WO2004008147A3 Diagnosis and prevention of cancer cell invasion |
| 05/27/2004 | WO2003102169B1 Anaerobe targeted enzyme-mediated prodrug therapy |
| 05/27/2004 | WO2003094697A3 Methods and compositions for correction of cardiac conduction disturbances |
| 05/27/2004 | WO2003081258A3 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs) |
| 05/27/2004 | WO2003015705A3 In situ immunization |
| 05/27/2004 | WO2003002155B1 Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies |
| 05/27/2004 | WO2002102854A3 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 05/27/2004 | WO2002092827A3 Corona-virus-like particles comprising functionally deleted genomes |
| 05/27/2004 | WO2002055721B1 Modular transfection systems based on nucleoprotein filaments |
| 05/27/2004 | WO2000073764A3 Composition and methods for the therapeutic use of an atonal-associated sequence |
| 05/27/2004 | WO1999046281A8 Novel polypeptides and nucleic acids encoding the same |
| 05/27/2004 | US20040103448 Using rodent animal model to monitor effectivenes of cell proliferation, viabilty and differentiation inhibitors |
| 05/27/2004 | US20040102623 Modulation of PAK1 expression |
| 05/27/2004 | US20040102622 Modulation of hepatocyte growth factor receptor expression |
| 05/27/2004 | US20040102621 Modulation of forkhead box C2 expression |
| 05/27/2004 | US20040102620 Msh4 gene splicing variant delta |
| 05/27/2004 | US20040102606 Histone H2A -derived peptides useful in gene delivery |
| 05/27/2004 | US20040102411 DNA vaccine against feline immunodeficiency virus |
| 05/27/2004 | US20040102410 In particular, invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors |
| 05/27/2004 | US20040102408 Method and medicament for inhibiting the expression of a given gene |
| 05/27/2004 | US20040102407 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
| 05/27/2004 | US20040102406 Phosphorothioate oligonucleotides directed to a subunit of an integrin vitronectin receptor to inhibit angiogenesis and/or metastasis |
| 05/27/2004 | US20040102403 Using compounds comprising oligonucleotides targeted to fibrillarin; for diagnosis and treatment of disease associated with expression of fibrillarin; proliferative disorders, cancer |
| 05/27/2004 | US20040102402 Using compounds comprising oligonucleotides targeted to nucleic acid encoding tissue factor; for diagnosis and treatment of disease associated with expression of tissue factor; cardiovascular disorders, cancer |
| 05/27/2004 | US20040102401 Using compounds comprising oligonucleotides targeted to nucleic acid encoding jagged 1; for diagnosis and treatment of disease associated with expression of jagged 1; developmental disorders, cancer |
| 05/27/2004 | US20040102400 Using compounds comprising oligonucleotides targeted to nucleic acid encoding UBE2G1; for diagnosis and treatment of disease associated with expression of UBE2G1; autoimmune, developmental, neurodegenerative disorders, cancer |
| 05/27/2004 | US20040102395 Modulation of IAP-like expression |
| 05/27/2004 | US20040102394 Using compositions comprising oligonucleotides targeted to nucleic acid encoding huntingtin interacting protein 2; for diagnosis and treatment of disease associated with expression of huntingtin interacting protein 2 |
| 05/27/2004 | US20040102393 Using compounds comprising oligonucleotides targeted to nucleic acid encoding heat shock protein 90-alpha for diagnosis and treatment of disease associated with expression of heat shock protein 90-alpha |
| 05/27/2004 | US20040102392 Modulation of ADAM15 expression |
| 05/27/2004 | US20040102388 Modified blood clotting factors and methods of use |
| 05/27/2004 | US20040102382 Targeting peptides |
| 05/27/2004 | US20040102379 Fibroblast growth factor homologous factors (FHFs) and methods of use |
| 05/27/2004 | US20040102376 Use of rgm and its modulators |
| 05/27/2004 | US20040102372 Therapeutic antiangiogenic compositions and methods |
| 05/27/2004 | US20040102371 Encoded amino acid sequences, DNAs encoding the proteins, recombinant vectors, culturing, drugs comprising the proteins or DNAs, antibodies, drug screening, for arteriosclerosis, hyperlipidemia, obesity or mellitus diabetes |
| 05/27/2004 | US20040101965 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 05/27/2004 | US20040101940 Identification of a new cytotoxic activity from the ink of aplysia punctata |
| 05/27/2004 | US20040101932 Compositions and methods for targeted enzymatic release of cell regulatory compounds |
| 05/27/2004 | US20040101931 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |